ASLAN Pharmaceuticals Limited Stock Taipei Exchange
Equities
6497
KYG054241099
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 314M 9.71M |
---|---|---|---|---|---|
Net income 2024 * | -2.36B -72.95M | Net income 2025 * | -1.77B -54.9M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.14
x | P/E ratio 2025 * |
-0.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99% |
Managers | Title | Age | Since |
---|---|---|---|
Carl Firth
FOU | Founder | 51 | 09-12-31 |
Kiran Asarpota
DFI | Director of Finance/CFO | 45 | 10-10-31 |
Chief Tech/Sci/R&D Officer | - | 22-03-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hoffman
BRD | Director/Board Member | 58 | 18-10-29 |
Andrew Howden
CHM | Chairman | 64 | 16-03-31 |
Carl Firth
FOU | Founder | 51 | 09-12-31 |
1st Jan change | Capi. | |
---|---|---|
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |